Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-07-02 DOI:10.2174/0115680096293516240607071915

Xia Li, Weiwei Chen, Shu Jiang, Lianlian Zhang, Hua Huang, Yanan Ji, Qinggan Ni, Chunhua Ling

{"title":"Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer.","authors":"Xia Li, Weiwei Chen, Shu Jiang, Lianlian Zhang, Hua Huang, Yanan Ji, Qinggan Ni, Chunhua Ling","doi":"10.2174/0115680096293516240607071915","DOIUrl":null,"url":null,"abstract":"Background: Sodium voltage-gated channel beta subunit 4 (SCN4B) plays a suppressive role in various tumors. However, the role of SCN4B in non-small cell lung cancer (NSCLC) is not yet clear. This study aims to investigate the expression of SCN4B in NSCLC patients and its correlation with prognosis.Methods: Firstly, the expression of SCN4B in non-small cell lung cancer (NSCLC) was analyzed using The Cancer Genome Atlas (TCGA) database. Then, differential expression genes (DEGs) were identified using R software. Next, DEG enrichment pathways were analyzed using the R package clusterProfiler. Protein-protein interaction networks were revealed through STRING analysis. A heatmap showed significant differential expression of SCN4B. Further analysis included examining SCN4B expression in a pan-cancer context and its correlation with 24 types of immune cells in NSCLC. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR), Western Blot, immunohistochemistry, and clinical data were used to validate SCN4B expression and prognostic value in NSCLC patients.Results: SCN4B mRNA expression in non-small cell lung cancer tissues was significantly lower than in adjacent normal tissues (p < 0.001). Clinical correlation analysis confirmed its association with clinical pathology. Gene set enrichment analysis (GSEA) and tumor immune-related analyses indicated that SCN4B is involved in NSCLC-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and participates in immune infiltration. qRT-PCR, Western Blot, and immunohistochemistry also confirmed that SCN4B is downregulated in NSCLC patients and is associated with poor prognosis.Conclusion: SCN4B is downregulated in tumor tissues of NSCLC patients and is associated with a poor prognosis.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096293516240607071915","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Sodium voltage-gated channel beta subunit 4 (SCN4B) plays a suppressive role in various tumors. However, the role of SCN4B in non-small cell lung cancer (NSCLC) is not yet clear. This study aims to investigate the expression of SCN4B in NSCLC patients and its correlation with prognosis.

Methods: Firstly, the expression of SCN4B in non-small cell lung cancer (NSCLC) was analyzed using The Cancer Genome Atlas (TCGA) database. Then, differential expression genes (DEGs) were identified using R software. Next, DEG enrichment pathways were analyzed using the R package clusterProfiler. Protein-protein interaction networks were revealed through STRING analysis. A heatmap showed significant differential expression of SCN4B. Further analysis included examining SCN4B expression in a pan-cancer context and its correlation with 24 types of immune cells in NSCLC. Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR), Western Blot, immunohistochemistry, and clinical data were used to validate SCN4B expression and prognostic value in NSCLC patients.

Results: SCN4B mRNA expression in non-small cell lung cancer tissues was significantly lower than in adjacent normal tissues (p < 0.001). Clinical correlation analysis confirmed its association with clinical pathology. Gene set enrichment analysis (GSEA) and tumor immune-related analyses indicated that SCN4B is involved in NSCLC-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and participates in immune infiltration. qRT-PCR, Western Blot, and immunohistochemistry also confirmed that SCN4B is downregulated in NSCLC patients and is associated with poor prognosis.

Conclusion: SCN4B is downregulated in tumor tissues of NSCLC patients and is associated with a poor prognosis.

查看原文本刊更多论文

SCN4B的低表达可预测非小细胞肺癌的不良预后

背景：钠电压门控通道 beta 亚基 4（SCN4B）在多种肿瘤中发挥抑制作用。然而，SCN4B 在非小细胞肺癌（NSCLC）中的作用尚不明确。本研究旨在探讨SCN4B在NSCLC患者中的表达及其与预后的相关性：首先，利用癌症基因组图谱（TCGA）数据库分析了SCN4B在非小细胞肺癌（NSCLC）中的表达。然后，使用 R 软件鉴定差异表达基因（DEG）。接着，使用 R 软件包 clusterProfiler 分析 DEG 富集途径。通过 STRING 分析揭示了蛋白质-蛋白质相互作用网络。热图显示了 SCN4B 的显著差异表达。进一步的分析包括研究 SCN4B 在泛癌症中的表达及其与 NSCLC 中 24 种免疫细胞的相关性。随后，研究人员利用定量实时聚合酶链反应（qRT-PCR）、Western Blot、免疫组化和临床数据验证了SCN4B在NSCLC患者中的表达和预后价值：结果：SCN4B mRNA在非小细胞肺癌组织中的表达明显低于邻近的正常组织（p < 0.001）。临床相关性分析证实其与临床病理相关。基因组富集分析（GSEA）和肿瘤免疫相关分析表明，SCN4B参与了NSCLC相关的京都基因组百科全书（KEGG）通路，并参与了免疫浸润：结论：SCN4B在NSCLC患者的肿瘤组织中下调，与预后不良有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464